DYN — Dyne Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$25.10
-$0.33 (-1.30%)
Dyne Therapeutics Inc (DYN) is a biotechnology company listed on NASDAQ. It is led by John G. Cox M.B.A., based in 1560 Trapelo Road, Waltham, MA, United States, 02451, with about 192 employees. Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Net income was -$334.3M. DYN currently screens at market cap $1.19B.
Use this DYN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DYN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DYN SEC filings page. Lician reads the product cache first so this HTML stays unique to Dyne Therapeutics Inc even when a live quote feed is slow.
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
DYN Key Statistics
Market Cap
$1.19B
Volume
938,636
Previous Close
$25.99
Day Range
$25.96 – $26.69
EPS
-$3.37
Revenue
$0.00
Net Income
-$317.42M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
192
DYN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$317.42M | -$235.94M | -$168.10M | -$149.29M |
| EPS (Diluted) | -$3.37 | -$3.95 | -$3.23 | -$2.93 |
Total Assets
$691.23M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$435.45M
Operating Cash Flow
-$292.37M
Free Cash Flow
$0.00
Dyne Therapeutics Inc Company Information
- CEO, President & Director
- John G. Cox M.B.A.
- Headquarters
- 1560 Trapelo Road, Waltham, MA, United States, 02451
- Website
- www.dyne-tx.com
- Phone
- 781 786 8230
- IPO / Founded
- 2020-09-17
- Sector
- Healthcare
- Industry
- Biotechnology